Indaptus Therapeutics (INDP) Total Non-Current Liabilities (2020 - 2024)
Indaptus Therapeutics (INDP) posted quarterly Total Non-Current Liabilities of $4007.0 for Q3 2024, down 95.79% year-over-year from $95237.0 in Q4 2023, and down 85.47% quarter-over-quarter from $27579.0 in Q2 2024.
Indaptus Therapeutics (INDP) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Indaptus Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $4007.0 for Q3 2024.
- In Q3 2024, Total Non-Current Liabilities fell 95.79% year-over-year to $4007.0; the TTM figure through Sep 2024 stood at $4007.0 (down 95.79% YoY), while the FY2023 annual figure was $73348.0, changed N/A from the prior year.
- Total Non-Current Liabilities for Q3 2024 stood at $4007.0, down from $27579.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.0 million in Q4 2020, with the low at $4007.0 in Q3 2024.
- The 5-year median for Total Non-Current Liabilities is $73105.0 (2021), against an average of $234850.6.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities plunged 96.1% in 2022, then soared 1824.37% in 2023.
- Indaptus Therapeutics' Total Non-Current Liabilities stood at $1.0 million in 2020, then plunged by 92.92% to $72862.0 in 2021, then plunged by 93.21% to $4949.0 in 2022, then soared by 1382.08% to $73348.0 in 2023, then slumped by 94.54% to $4007.0 in 2024.
- Business Quant data shows INDP's Total Non-Current Liabilities at $4007.0 in Q3 2024, $27579.0 in Q2 2024, and $50664.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 4,007.00 |
| Jun 30, 2024 | 27,579.00 |
| Mar 31, 2024 | 50,664.00 |
| Dec 31, 2023 | 73,348.00 |
| Sep 30, 2023 | 95,237.00 |
| Jun 30, 2023 | 116,170.00 |
| Mar 31, 2023 | 136,669.00 |
| Sep 30, 2022 | 4,949.00 |
| Jun 30, 2022 | 27,907.00 |
| Mar 31, 2022 | 50,516.00 |
| Dec 31, 2021 | 72,862.00 |
| Jun 30, 2021 | 716,000.00 |
| Mar 31, 2021 | 883,000.00 |
| Dec 31, 2020 | 1.03 Mn |